Milo Biotechnology Financing
Milo Biotechnology Llc, Limited Liability Company just filed form D about $1.50 million debt financing. The date of first sale was 2016-05-26. Milo Biotechnology was able to sell $1.22 million. That is 81.00% of the offering. The total private financing amount was $1.50 million. The financing document was filed on 2016-11-08. The reason for the financing was: unspecified. The fundraising still has about $285,000 more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Milo Biotechnology is based in Alabama. The company’s business is Pharmaceuticals. The form D was signed by Paul A Hawkins Manager and Chief Executive Officer. The company was incorporated in 2011. The filler’s address is: 11471, Ste 214B, Cleveland, Oh, Ohio, 44106. Paul A. Hawkins is the related person in the form and it has address: 11471 Euclid Avenue, Ste 214B, Cleveland, Oh, Ohio, 44106. Link to Milo Biotechnology Filing: 000167608216000002.
Analysis of Milo Biotechnology Offering
On average, companies in the Pharmaceuticals sector, sell 60.90% of the total offering amount. Milo Biotechnology sold 81.00% of the offering. The fundraising is still open. Could this mean that the trust in Milo Biotechnology is high? The average investment size for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 118.53% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this fundraising was set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Milo Biotechnology Also
The Form D signed by Paul A Hawkins might help Milo Biotechnology Llc’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.